General Enquiries



Vancouver Prostate Centre

336A-2660 Oak Street

Vancouver, BC, Canada

V6H 3Z6




Review Committe

Dr. Hui Xue (co-chair)

Dr. Dong Lin (co-chair)

Dr. Jennifer Niu

Dr. Fiona Zhang

Dr. Nelson Wong

Dr. Cindy Dong (secretary)


The Living Tumor Laboratory (LTL) welcomes collaborations using PDX models and has been endeavored to help both academic collaborators and industry partners achieve their research goals and promote the implementation of knowledge in the field of translational cancer research.

To ensure a smooth and productive collaboration, it is important for potential collaborators to be aware of that 1) a collaborative research plan should first be discussed; 2)upon consensus of the Review Committee and the collaborator, an academic collaboration agreement or collaborative research service agreement for industry partners should be in place before the collaboration commences; and 3) in vivo studies using LTL PDX models are resources-consuming. The following are a few specific points for considerations:

1. Cost

Since LTL does not receive any core institutional financial support, academic collaborators are expected to provide funding to cover basic costs, such as costs of animals, manpower, and consumables. If the collaboration is under a research service contract, terms and conditions will be discussed accordingly.

2. Time

Due to the varied properties of the LTL cancer models and the availability of LTL team members, time required for model recovery, passaging, and expanding varies, ranging from four to nine months.

3. Authorship

As accepted norms vary across disciplines, it is important to have a discussion on authorship at the start of the collaboration.

4. Cross-institutional research policies

All collaboration with the Living Tumor Laboratory will follow guidelines and policies of our institutions. In turn, it is important for researchers to be aware of their own institutions' requirements and to discuss these with the research team.


If you are interested in collaboration with the Living Tumor Laboratory, please consider providing a brief summary of collaboration plan to address your requirements as well as the issues mentioned above. This allows members of our Collaboration Review Committee to assess the feasibility of collaboration basing on their current workload and make a collective decision accordingly. We certainly treasure opportunities to collaborate; however, with limited resources and personnel, our review committee may not be able to grant all collaboration requests. We covet your understanding and we apologize in advance if we are unable to accommodate your requests. Please send your enquiry and collaboration requests to